EGFRvIII-directed CAR-T cell tharapy (Novartis/University of Pennsylvania) |
LXF-821 |
Phase 1 Clinical |
University Of Pennsylvania, Novartis Pharma Ag |
Glioblastoma |
Details
|
Programmed cell death 1 antibody (Sun Yat-sen University) |
|
Phase 2 Clinical |
Sun Yat-Sen University |
Carcinoma, Hepatocellular |
Details
|
9MW1111 |
9MW1111; 9MW-1111; 9-MW1111; 9-MW-1111 |
Phase 1 Clinical |
Mabwell (Shanghai) Bioscience Co Ltd |
Solid tumours |
Details
|
EBV-Specific TCR-T Cell therapy (Xinqiao Hospital of Chongqing) |
|
Phase 2 Clinical |
Xinqiao Hospital, Army Medical University |
Squamous Cell Carcinoma of Head and Neck |
Details
|
ONO-4685 |
ONO-4685 |
Phase 1 Clinical |
Merus |
Autoimmune Diseases; Lymphoma, T-Cell |
Details
|
Anti-CTLA-4/PD-1 expressing EGFR-CAR-T |
|
Phase 2 Clinical |
Shanghai Cell Therapy Research Institute |
Solid tumours |
Details
|
TY-101 |
TY-101; TY101 |
Phase 2 Clinical |
Tayu Huaxia Biotech Medical Group Co Ltd |
Solid tumours; Lymphoma |
Details
|
Recombinant humanized anti-PD-1 monoclonal antibody (Shanghai CP Guojian) |
|
Phase 2 Clinical |
Shanghai Cp Guojian Pharmaceutical Co Ltd |
Solid tumours; Sarcoma |
Details
|
Izuralimab |
XmAb-104; XmAb-23104 |
Phase 1 Clinical |
Xencor |
Nasopharyngeal Carcinoma; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Uterine Cervical Neoplasms; Melanoma; Endometrial Neoplasms; Colorectal Neoplasms; Sarcoma; Breast Neoplasms; Solid tumours; Small Cell Lung Carcinoma; Pancreatic Neoplasms; Carcinoma, Transitional Cell; Squamous Cell Carcinoma of Head and Neck; Carcinoma, Renal Cell; Stomach Neoplasms; Esophageal Neoplasms |
Details
|
RO-7121661 |
RG-7769; RO-7121661 |
Phase 2 Clinical |
F. Hoffmann-La Roche Ltd |
Solid tumours; Small Cell Lung Carcinoma; Esophageal Squamous Cell Carcinoma; Melanoma; Carcinoma, Non-Small-Cell Lung |
Details
|
ONCR-177 |
ONCR-177 |
Phase 1 Clinical |
Oncorus |
Solid tumours; Liver Neoplasms; Squamous Cell Carcinoma of Head and Neck; Skin Neoplasms; Triple Negative Breast Neoplasms; Breast Neoplasms; Colorectal Neoplasms; Melanoma |
Details
|
SSGJ-705 |
SSGJ-705 |
Phase 1 Clinical |
Shanghai Cp Guojian Pharmaceutical Co Ltd |
Solid tumours |
Details
|
RG-6279 |
RG-6279 |
Phase 1 Clinical |
F. Hoffmann-La Roche Ltd |
Solid tumours |
Details
|
JS-201 |
JS-201 |
Phase 1 Clinical |
Shanghai Junshi Biosciences Co Ltd |
Neoplasms |
Details
|
PD-1 knockout engineered T cells (Chengdu MedGenCell) |
|
Phase 2 Clinical |
West China Hospital Of Sichuan University, Chengdu Medgencell |
Lung Neoplasms; Melanoma; Carcinoma, Non-Small-Cell Lung |
Details
|
LBL-015 |
LBL-015 |
Phase 2 Clinical |
Nanjing Leads Biolabs Co Ltd |
Solid tumours |
Details
|
Anti-CTLA-4 and PD-1 CAR-T cell therapy (Shanghai Cell Therapy Research Institute) |
|
Phase 2 Clinical |
Shanghai Cell Therapy Research Institute |
Neoplasms |
Details
|
RB-0004 |
RB-0004 |
Phase 1 Clinical |
Reyoung Pharmaceutical Co Ltd |
Solid tumours; Lymphoma |
Details
|
EBV-specific TCR-T cell with anti-PD1 auto-secreted element |
|
Phase 2 Clinical |
Tcrcure Biopharma Ltd |
Squamous Cell Carcinoma of Head and Neck |
Details
|
MK-3475A |
MK-3475A |
|
Merck Sharp & Dohme Corp |
|
Details
|
Vudalimab |
XmAb-20717; XmAb-717 |
Phase 2 Clinical |
Xencor |
Nasopharyngeal Carcinoma; Carcinoma, Non-Small-Cell Lung; Carcinoma, Hepatocellular; Melanoma; Uterine Cervical Neoplasms; Carcinoma, Squamous Cell; Fallopian Tube Neoplasms; Carcinoma, Neuroendocrine; Thymoma; Endometrial Neoplasms; Colorectal Neoplasms; Astrocytoma; Vulvar Neoplasms; Breast Neoplasms; Ovarian Neoplasms; Cholangiocarcinoma; Prostatic Neoplasms; Adnexal Diseases; Mesothelioma; Small Cell Lung Carcinoma; Carcinoma, Transitional Cell; Carcinoma, Ovarian Epithelial; Squamous Cell Carcinoma of Head and Neck; Carcinoma, Basal Cell; Carcinoma, Renal Cell; Stomach Neoplasms; Esophageal Neoplasms; Solid tumours |
Details
|
CC-90006 |
C-90006; CC-90006 |
Phase 1 Clinical |
Anaptysbio |
Autoimmune Diseases; Psoriasis |
Details
|
PD-1 knockout engineered T cells (Cell Biotech) |
|
Phase 1 Clinical |
Cell Biotech |
Carcinoma, Renal Cell; Urinary Bladder Neoplasms; Prostatic Neoplasms |
Details
|
Multiple target antigen stimulating cell therapy (HengRui YuanZheng Biotechnology) |
|
Phase 1 Clinical |
Hengrui Yuanzheng (Shanghai) Biotechnology Co Ltd |
Solid tumours; Stomach Neoplasms |
Details
|
W0180 |
|
Phase 1 Clinical |
Pierre Fabre Medicament |
Solid tumours |
Details
|
SI-B003 |
SI-B003 |
Phase 1 Clinical |
Sichuan Baili Pharmaceutical Co Ltd |
Solid tumours; Carcinoma, Renal Cell; Stomach Neoplasms; Carcinoma, Transitional Cell; Triple Negative Breast Neoplasms; Colorectal Neoplasms; Neoplasm Metastasis; Melanoma; Carcinoma, Non-Small-Cell Lung; Uterine Cervical Neoplasms |
Details
|
PE0105 |
PE-0105 |
Phase 1 Clinical |
Shanghai Yunyi Health Technology Development Co Ltd |
Neoplasms |
Details
|
BAT-1308 |
BAT-1308 |
Phase 1 Clinical |
Bio-Thera Solutions Ltd |
Solid tumours |
Details
|
PD-1 knockout engineered T cells (Anhui Kedgene Biotechnology) |
|
Phase 2 Clinical |
Anhui Korton Biological Technology Co Ltd, Hangzhou Cancer Hospital |
Esophageal Neoplasms |
Details
|
BCMA-PD1 CAR T cell therapy (General Hospital of the People's Liberation Army) |
|
Phase 2 Clinical |
People'S Liberation Army General Hospital Military Service |
Multiple Myeloma |
Details
|
BCD-217 |
BCD-217 |
Phase 2 Clinical |
Biocad |
Melanoma |
Details
|
CD19-PD1-CAR T cell therapy (Chinese PLA General Hospital) |
|
Phase 2 Clinical |
Pla General Hospital |
Lymphoma, B-Cell |
Details
|
89Zr-N-sucDf-pembrolizumab |
|
Phase 1 Clinical |
Merck & Co Inc, Umcg The University Medical Center Groningen |
Carcinoma, Non-Small-Cell Lung; Melanoma |
Details
|
CD-200-AR-L |
CD-200-AR-L; hP-1-A-8 |
Phase 1 Clinical |
University Of Minnesota |
Glioblastoma |
Details
|
Recombinant humanized anti-PD-1 monoclonal antibody (Anhui Anke Biotechnology) |
|
Phase 2 Clinical |
Anhui Anke Biotechnology (Group) Co Ltd |
Esophageal Neoplasms; Neoplasms; Carcinoma, Transitional Cell; Triple Negative Breast Neoplasms; Lymphoma; Lung Neoplasms |
Details
|
LZM-009 |
LZM-009 |
Phase 2 Clinical |
Livzon(Group) Pharmaceutical Factory |
Solid tumours; Thymoma; Carcinoma, Non-Small-Cell Lung |
Details
|
QL1604 |
QL1604; QL-1604 |
Phase 3 Clinical |
Qilu Pharmaceutical Co Ltd |
Solid tumours; Uterine Cervical Neoplasms; Adenocarcinoma |
Details
|
SL-279252 |
TAK-252; SL-279252 |
Phase 1 Clinical |
Takeda Pharmaceutical Co Ltd, Shattuck Labs |
Carcinoma, Renal Cell; Squamous Cell Carcinoma of Head and Neck; Esophageal Neoplasms; Carcinoma, Transitional Cell; Hodgkin Disease; Lymphoma, Large B-Cell, Diffuse; Melanoma; Adenocarcinoma; Carcinoma, Non-Small-Cell Lung |
Details
|
MEDI-0680 |
AMP-514; MEDI-0680 |
Phase 2 Clinical |
Medimmune |
Kidney Neoplasms; Lymphoma, B-Cell; Carcinoma, Renal Cell |
Details
|
MiHA-loaded PD-L silenced DC vaccination (Radboud University) |
|
Phase 2 Clinical |
Radboud University Nijmegen |
Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Multiple Myeloma; Leukemia, Myeloid, Acute; Lymphoma, Non-Hodgkin |
Details
|
Sym-021 |
Sym-021 |
Phase 1 Clinical |
Symphogen |
Solid tumours; Lymphoma; Neoplasm Metastasis |
Details
|
YBL-006 |
YBL-006; YBL 006 |
Phase 1 Clinical |
|
Solid tumours |
Details
|
BA1104 |
LY-01015; BA-1104 |
Phase 1 Clinical |
Luye Pharma Group Ltd |
Liver Neoplasms; Carcinoma, Renal Cell; Stomach Neoplasms; Urinary Bladder Neoplasms; Glioma; Carcinoma, Non-Small-Cell Lung; Melanoma |
Details
|
Recombinant human anti-PD-1 monoclonal antibody(Hec Biological) |
|
Phase 1 Clinical |
Dongguan City Hec Biological Medicine Res And Development Co Ltd |
Stomach Neoplasms; Esophageal adenocarcinoma |
Details
|
T3011疱疹病毒(深圳市亦诺微医药) |
MVR-T3011 |
Phase 2 Clinical |
Immvira Co Ltd |
Solid tumours; Liver Neoplasms; Head and Neck Neoplasms; Esophageal Neoplasms; Mesothelioma; Breast Neoplasms; Lymphoma; Lung Neoplasms; Melanoma; Carcinoma, Non-Small-Cell Lung; Neoplasm Metastasis |
Details
|
EMB-02 |
EMB-02 |
Phase 2 Clinical |
Shanghai Epimab Biotherapeutics, Inc |
Solid tumours |
Details
|
PD-1 knockout EBV-CTL (Nanjing Medical University) |
|
Phase 2 Clinical |
Nanjing Medical University |
Stomach Neoplasms; Hodgkin Disease; Lymphoma, Large B-Cell, Diffuse; Nasopharyngeal Neoplasms; Lymphoma |
Details
|
Recombinant human PD-1 antibody herpes simplex virus |
|
Phase 1 Clinical |
Yangsheng Tang Co Ltd, Xiamen University |
Liver Neoplasms; Head and Neck Neoplasms; Pancreatic Neoplasms; Urinary Bladder Neoplasms; Colorectal Neoplasms; Lung Neoplasms; Melanoma; Uterine Cervical Neoplasms |
Details
|
IMU-201 |
IMU-201 |
Phase 1 Clinical |
Imugene |
Adenocarcinoma of Lung; Carcinoma, Large Cell; Carcinoma, Squamous Cell; Lung Neoplasms; Carcinoma, Non-Small-Cell Lung |
Details
|
HerinCAR-PD1 |
|
Phase 2 Clinical |
Ningbo Cancer Hospital |
Solid tumours |
Details
|
CD19 PD-1/CD28 CAR-T Cell Therapy (Second Affiliated Hospital School Of Zhejiang University School Of Medicine) |
|
Phase 1 Clinical |
Second Affiliated Hospital Of Zhejiang University School Of Medicine |
Lymphoma, B-Cell; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Follicular; Lymphoma, Mantle-Cell; Primary mediastinal B cell lymphoma |
Details
|
Recombinant human anti-PD-1 monoclonal antibody(Cspc Pharmaceutical Technology ,Shijiazhuang) |
|
Phase 1 Clinical |
Cspc Pharmaceutical Technology (Shijiazhuang) Co Ltd |
Bile Duct Neoplasms |
Details
|
STW204 |
STW-204; AI025; AI-025 |
Phase 1 Clinical |
Suzhou Stainwei Biotech Inc |
Solid tumours; Neoplasms |
Details
|
Recombinant humanized anti-PD-1 monoclonal antibody (Shanxi Wichida Bright Pharmaceutical) |
|
Phase 1 Clinical |
Shanxi Weiqidaguangming Pharmaceutical Co Ltd |
Solid tumours |
Details
|
HPV E6-specific TCR-T cells |
SIM-325; TC-E202 |
Phase 1 Clinical |
Tcrcure Biopharma Ltd |
Squamous Cell Carcinoma of Head and Neck; Uterine Cervical Neoplasms |
Details
|
INSIX RA (Indus Biotech) |
|
Clinical |
Indus Biotech Pvt Ltd |
Arthritis, Rheumatoid; Inflammation |
Details
|
CMAB-819 |
CMAB8-19 |
Phase 1 Clinical |
Sinomab Bioscience Ltd |
Squamous Cell Carcinoma of Head and Neck; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung |
Details
|
Cetrelimab |
JNJ-3283; JNJ-63723283 |
Phase 3 Clinical |
Johnson & Johnson |
Neoplasms; Carcinoma, Transitional Cell; Multiple Myeloma; Urinary Bladder Neoplasms |
Details
|
GNR-051 |
GNR-051 |
Phase 1 Clinical |
Generium Pharmaceuticals |
Carcinoma, Renal Cell; Melanoma; Carcinoma, Non-Small-Cell Lung |
Details
|
MW-11 |
MW-11 |
Phase 1 Clinical |
Mabwell (Shanghai) Bioscience Co Ltd |
Solid tumours; Carcinoma, Renal Cell; Stomach Neoplasms; Carcinoma, Transitional Cell; Nasopharyngeal Neoplasms; Hodgkin Disease; Breast Neoplasms; Colorectal Neoplasms; Endometrial Neoplasms; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Melanoma |
Details
|
MEDI-5752 |
MEDI-5752 |
Phase 1 Clinical |
Medimmune Llc |
Solid tumours; Carcinoma, Renal Cell; Neoplasms |
Details
|
AZD-7789 |
AZD-7789 |
Phase 2 Clinical |
AstraZeneca Ag |
Carcinoma, Non-Small-Cell Lung |
Details
|
IBI-318(Innovent Biologics/Eli Lilly And Company) |
LY-3434172; LY3434172; IBI-318 |
Phase 2 Clinical |
Innovent Biologics(Suzhou) Co Ltd, Eli Lilly And Company |
Small Cell Lung Carcinoma; Lymphoma, Extranodal NK-T-Cell; Carcinoma, Squamous Cell; Carcinoma, Hepatocellular |
Details
|
Treprilimab |
|
Clinical |
Sun Yat-Sen University |
Oropharyngeal Neoplasms |
Details
|
Recombinant humanized anti-PD-1 monoclonal antibody (Bio-Thera) |
BAT-1306 |
Phase 2 Clinical |
Bio-Thera Solutions Ltd |
Solid tumours; Stomach Neoplasms |
Details
|
Rituximab/Paclitaxel |
AR-160 |
Phase 1 Clinical |
Mayo Clinic |
Lymphoma, Non-Hodgkin |
Details
|
Pimivalimab |
JTX-4014 |
Phase 2 Clinical |
Jounce Therapeutics |
Neoplasms; Carcinoma, Non-Small-Cell Lung |
Details
|
AZD-2936 |
AZD-2936 |
Phase 2 Clinical |
Astrazeneca Plc |
Carcinoma, Non-Small-Cell Lung |
Details
|
HX-009 |
HX-009 |
Phase 2 Clinical |
Hangzhou Hansi Biomedicine Co Ltd, Wuhan Hanxiong Biotechnology Co Ltd |
Liver Neoplasms; Hematologic Neoplasms; Solid tumours; Stomach Neoplasms; Carcinoma, Renal Cell; Squamous Cell Carcinoma of Head and Neck; Lymphoma; Carcinoma, Non-Small-Cell Lung; Melanoma |
Details
|
SSI-361 |
LVGN-3616; SSI-361 |
Phase 2 Clinical |
Lyvgen Biopharma(HK)Ltd |
Neoplasms |
Details
|
SSGJ-706 |
SSGJ-706 |
Phase 1 Clinical |
Shanghai Cp Guojian Pharmaceutical Co Ltd |
Solid tumours; Lymphoma |
Details
|
QL-1706 |
QL-1706; PSB-205 |
Phase 2 Clinical |
Qilu Pharmaceutical Co Ltd |
Solid tumours; Liver Neoplasms; Neoplasms; Uterine Cervical Neoplasms |
Details
|
Tebotelimab |
MGD-013; PD-1 X LAG-3 |
Phase 3 Clinical |
Macrogenics |
Small Cell Lung Carcinoma; Carcinoma, Non-Small-Cell Lung; Melanoma; Neoplasm Metastasis; Uterine Cervical Neoplasms; Carcinoma, Hepatocellular; Adenocarcinoma; Endometrial Neoplasms; Cholangiocarcinoma; Solid tumours; Triple Negative Breast Neoplasms; Squamous Cell Carcinoma of Head and Neck; Esophageal Neoplasms; Stomach Neoplasms; Hematologic Neoplasms; Ovarian Neoplasms; Head and Neck Neoplasms; Biliary Tract Neoplasms |
Details
|
ZG-005 |
ZG-005 |
Phase 2 Clinical |
Suzhou Zelgen Biopharmaceuticals Co Ltd |
Solid tumours |
Details
|
609-A |
609-A |
Phase 2 Clinical |
Shenyang Sunshine Pharmaceutical Co Ltd |
Solid tumours; Sarcoma |
Details
|
dPD-1 hCD19 CART cell therapy (Innovative Cellular Therapeutics) |
ICTCAR-014 |
Phase 2 Clinical |
Innovative Cellular Therapeutics Co Ltd |
Lymphoma, Non-Hodgkin |
Details
|
PH-762 |
PH-762 |
Phase 1 Clinical |
|
Breast Neoplasms; Melanoma |
Details
|
Rulonilimab |
F-520 |
Phase 2 Clinical |
Shandong New Time Pharmaceutical Co Ltd |
Solid tumours; Lymphoma, T-Cell, Peripheral; Carcinoma, Transitional Cell; Lymphoma, Large B-Cell, Diffuse; Neurolymphomatosis; Lymphoma; Uterine Cervical Neoplasms |
Details
|
NIR-178 |
PBF-509; NIR-178 |
Phase 2 Clinical |
Palobiofarma |
Ovarian Neoplasms; Head and Neck Neoplasms; Solid tumours; Carcinoma, Renal Cell; Carcinoma; Triple Negative Breast Neoplasms; Lymphoma, Large B-Cell, Diffuse; Pancreatic Neoplasms; Prostatic Neoplasms, Castration-Resistant; Breast Neoplasms; Prostatic Neoplasms; Colorectal Neoplasms; Carcinoma, Pancreatic Ductal; Lung Neoplasms; Melanoma; Carcinoma, Non-Small-Cell Lung |
Details
|
Lorigerlimab |
MGD-019 |
Phase 1 Clinical |
Macrogenics |
Skin Melanoma; Solid tumours; Prostatic Neoplasms; Colorectal Neoplasms; Carcinoma, Non-Small-Cell Lung |
Details
|
Recombinant human anti-PD-1 monoclonal antibody(Sumgen) |
SG-001; SYSA1802 |
Phase 2 Clinical |
Hangzhou Sumgen Biotechnology Co Ltd |
Solid tumours; Biliary Tract Neoplasms; Triple Negative Breast Neoplasms; Carcinoma, Ovarian Epithelial; Mesothelioma; Cholangiocarcinoma; Peritoneal Neoplasms; Lymphoma; Fallopian Tube Neoplasms; Gallbladder Neoplasms; Uterine Cervical Neoplasms; Carcinoma, Non-Small-Cell Lung |
Details
|
Nofazinlimab |
CS-1003 |
Phase 3 Clinical |
Cstone Pharmaceuticals |
Solid tumours; Neoplasms; Lymphoma; Carcinoma, Hepatocellular |
Details
|
ABBV-1882 |
ABBV-1882 |
Phase 1 Clinical |
Abbvie Inc |
HIV Infections |
Details
|
IBI-321 |
IBI-321 |
Phase 1 Clinical |
Innovent Biologics(Suzhou) Co Ltd |
Solid tumours |
Details
|
IBI-319 |
IBI-319 |
Phase 1 Clinical |
Innovent Biologics(Suzhou) Co Ltd |
Neoplasms |
Details
|
Finotonlimab |
SCT-I10A |
Phase 3 Clinical |
SinoCelltech Ltd |
Solid tumours; Squamous Cell Carcinoma of Head and Neck; Colorectal Neoplasms; Carcinoma, Squamous Cell; Esophageal Squamous Cell Carcinoma; Lymphoma; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung |
Details
|
Fidasimtamab |
IBI-315 |
Phase 1 Clinical |
Hanmi Pharmaceutical Co Ltd, Innovent Biologics(Suzhou) Co Ltd |
Solid tumours |
Details
|
MAX-10181 |
MAX-10181; MAX-1 |
Phase 1 Clinical |
Guangzhou Maxinovel Pharmaceiticals Co Ltd |
Solid tumours |
Details
|
Zeluvalimab |
AMG-404 |
Phase 2 Clinical |
Amgen Inc |
Solid tumours; Small Cell Lung Carcinoma; Prostatic Neoplasms; Precursor Cell Lymphoblastic Leukemia-Lymphoma |
Details
|
Nivolumab/Relatlimab |
BMS-936558/BMS-986016; BMS-986213 |
Phase 3 Clinical |
Bristol-Myers Squibb Company |
Solid tumours; Stomach Neoplasms; Esophageal Neoplasms; Melanoma |
Details
|
Rosnilimab |
ANB-030 |
Phase 2 Clinical |
Anaptysbio Inc |
Alopecia Areata |
Details
|
Budigalimab |
ABBV-181 |
Phase 2 Clinical |
Abbvie Inc |
HIV Infections; Head and Neck Neoplasms; Solid tumours; Ovarian Neoplasms; Squamous Cell Carcinoma of Head and Neck; Triple Negative Breast Neoplasms; Pancreatic Neoplasms; Small Cell Lung Carcinoma; Colorectal Neoplasms; Carcinoma, Non-Small-Cell Lung |
Details
|
CA-170 |
AUPM-170; CA-170 |
Phase 1 Clinical |
Aurigene |
Solid tumours |
Details
|
AMG-256 |
AMG-256 |
Phase 1 Clinical |
Amgen Inc |
Solid tumours |
Details
|
Pembrolizumab/Quavonlimab |
MK-1308A |
Phase 3 Clinical |
Merck Sharp & Dohme Corp, Msd Ireland (Carlow), Moshadong R & D (China) Co Ltd |
Solid tumours; Carcinoma, Renal Cell; Small Cell Lung Carcinoma; Colorectal Neoplasms; Carcinoma, Hepatocellular; Melanoma |
Details
|
Spartalizumab(Novartis Pharma) |
PDR-001 |
Phase 3 Clinical |
Novartis Pharma Ag |
Lymphoma; Neuroendocrine Tumors; Nasopharyngeal Carcinoma; Breast Neoplasms; Prostatic Neoplasms; Sarcoma; Gastrointestinal Stromal Tumors; Colorectal Neoplasms; Bone Marrow Diseases; Primary Myelofibrosis; Carcinoma, Pancreatic Ductal; Endometrial Neoplasms; Chordoma; Lung Neoplasms; Esophageal Squamous Cell Carcinoma; Leukemia, Myeloid, Acute; Sarcoma, Alveolar Soft Part; Carcinoma, Squamous Cell; Esophageal adenocarcinoma; Carcinoma, Non-Small-Cell Lung; Melanoma; Adenocarcinoma; Carcinoma, Hepatocellular; Persistent Fetal Circulation Syndrome; Stomach Neoplasms; Ovarian Neoplasms; Head and Neck Neoplasms; Leukemia, Myeloid; Liver Neoplasms; Leukemia; Hematologic Diseases; Kidney Neoplasms; Preleukemia; Carcinoma, Renal Cell; Carcinoma; Squamous Cell Carcinoma of Head and Neck; Solid tumours; Triple Negative Breast Neoplasms; Pancreatic Neoplasms; Myelodysplastic Syndromes; Leukemia, Myelomonocytic, Chronic; Thyroid Carcinoma, Anaplastic; Small Cell Lung Carcinoma; Lymphoma, Large B-Cell, Diffuse; Neoplasm |
Details
|
Ivonescimab |
AK-112 |
Phase 3 Clinical |
Zhongshan Akeso Biopharma Co Ltd |
Ovarian Neoplasms; Solid tumours; Small Cell Lung Carcinoma; Neoplasms; Triple Negative Breast Neoplasms; Genital Neoplasms, Female; Endometrial Neoplasms; Carcinoma, Non-Small-Cell Lung; Uterine Cervical Neoplasms; Neoplasm Metastasis |
Details
|
Mavezelimab/Pembrolizumab |
MK-4280A |
Phase 3 Clinical |
Msd Ireland (Carlow) Merck Sharp & Dohme Corp, Moshadong R & D (China) Co Ltd |
Solid tumours; Carcinoma, Renal Cell; Colorectal Neoplasms; Carcinoma, Non-Small-Cell Lung |
Details
|
Peramprizumab |
|
Phase 2 Clinical |
Sun Yat-Sen University |
Nasopharyngeal Carcinoma |
Details
|
LY-3462817 |
LY-3462817 |
Phase 2 Clinical |
Eli Lilly And Company |
Arthritis, Rheumatoid; Psoriasis |
Details
|
RO-7247669 |
RO-7247669 |
Phase 2 Clinical |
F. Hoffmann-La Roche Ltd |
Solid tumours; Liver Neoplasms; Esophageal Squamous Cell Carcinoma; Melanoma; Carcinoma, Non-Small-Cell Lung |
Details
|
Retifanlimab |
INCMGA-0012; INCMGA-00012; MGA-012 |
Phase 3 Clinical |
Macrogenics |
Urinary Bladder Neoplasms; Carcinoma, Hepatocellular; Gastrointestinal Neoplasms; Melanoma; Neoplasm Metastasis; Carcinoma, Endometrioid; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Carcinoma, Pancreatic Ductal; Endometrial Neoplasms; Colorectal Neoplasms; Prostatic Neoplasms; Head and Neck Neoplasms; Carcinoma, Transitional Cell; Triple Negative Breast Neoplasms; Carcinoma, Renal Cell; Esophageal Neoplasms; Carcinoma, Merkel Cell; Anus Neoplasms; Stomach Neoplasms; Squamous Cell Carcinoma of Head and Neck; Ovarian Neoplasms; Solid tumours |
Details
|
Sasanlimab |
PF-06801591; PF-6801591; RN-888 |
Phase 3 Clinical |
Pfizer Pharmaceuticals Ltd (China) |
Carcinoma, Transitional Cell; Melanoma; Carcinoma, Non-Small-Cell Lung; Endometrial Neoplasms; Carcinoma, Squamous Cell; Colorectal Neoplasms; Bile Duct Neoplasms; Prostatic Neoplasms; Sarcoma; Urinary Bladder Neoplasms; Solid tumours; Pancreatic Neoplasms; Carcinoma, Renal Cell; Squamous Cell Carcinoma of Head and Neck; Carcinoma; Esophageal Neoplasms; Stomach Neoplasms; Liver Neoplasms; Head and Neck Neoplasms; Ovarian Neoplasms |
Details
|
PF-07209960 |
PF-07209960 |
Phase 1 Clinical |
Pfizer Inc |
Squamous Cell Carcinoma of Head and Neck; Carcinoma, Renal Cell; Carcinoma, Transitional Cell; Carcinoma, Ovarian Epithelial; Colorectal Neoplasms; Carcinoma, Non-Small-Cell Lung |
Details
|
Pembrolizumab/Vibostolimab |
MK-7684A |
Phase 3 Clinical |
|
Hematologic Neoplasms; Esophageal Neoplasms; Squamous Cell Carcinoma of Head and Neck; Triple Negative Breast Neoplasms; Cholangiocarcinoma; Lung Neoplasms; Gallbladder Neoplasms; Endometrial Neoplasms; Uterine Cervical Neoplasms; Carcinoma, Non-Small-Cell Lung; Carcinoma, Hepatocellular |
Details
|
SHR-1901 |
SHR-1901 |
Phase 1 Clinical |
Suzhou Suncadia Biopharmaceuticals Co Ltd |
Neoplasms |
Details
|
Pembrolizumab biosimilar (biocad) |
BCD-201 |
Phase 1 Clinical |
Biocad |
Solid tumours |
Details
|
Ezabenlimab |
BI-754091 |
Phase 2 Clinical |
C.H. Boehringer Sohn Ag & Co. Kg |
Head and Neck Neoplasms; Solid tumours; Rectal Neoplasms; Squamous Cell Carcinoma of Head and Neck; Pancreatic Neoplasms; Colonic Neoplasms; Colorectal Neoplasms; Carcinoma, Squamous Cell; Melanoma; Carcinoma, Non-Small-Cell Lung; Neoplasm Metastasis; Gastrointestinal Neoplasms |
Details
|